PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.61%
Positive revenue growth while 3088.T is negative. John Neff might see a notable competitive edge here.
7.07%
Positive gross profit growth while 3088.T is negative. John Neff would see a clear operational edge over the competitor.
23.00%
Positive EBIT growth while 3088.T is negative. John Neff might see a substantial edge in operational management.
18.46%
Positive operating income growth while 3088.T is negative. John Neff might view this as a competitive edge in operations.
42.27%
Positive net income growth while 3088.T is negative. John Neff might see a big relative performance advantage.
42.25%
Positive EPS growth while 3088.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
42.25%
Positive diluted EPS growth while 3088.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.00%
Share reduction while 3088.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3088.T is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
22.22%
Dividend growth of 22.22% while 3088.T is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
65.40%
10Y revenue/share CAGR 1.25-1.5x 3088.T's 51.95%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
61.06%
5Y revenue/share CAGR above 1.5x 3088.T's 6.28%. David Dodd would look for consistent product or market expansions fueling outperformance.
34.47%
3Y revenue/share CAGR above 1.5x 3088.T's 6.34%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-100.00%
Negative 10Y OCF/share CAGR while 3088.T stands at 100.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
155.91%
Net income/share CAGR at 75-90% of 3088.T's 202.56%. Bill Ackman would press for strategic moves to boost long-term earnings.
137.88%
5Y net income/share CAGR above 1.5x 3088.T's 67.11%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
84.91%
3Y net income/share CAGR similar to 3088.T's 87.50%. Walter Schloss would attribute it to shared growth factors or demand patterns.
215.84%
10Y equity/share CAGR above 1.5x 3088.T's 118.86%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
132.15%
5Y equity/share CAGR above 1.5x 3088.T's 39.55%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
65.78%
3Y equity/share CAGR above 1.5x 3088.T's 21.92%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
-8.33%
Cut dividends over 10 years while 3088.T stands at 37335.38%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-8.33%
Negative 5Y dividend/share CAGR while 3088.T stands at 133.33%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
57.14%
3Y dividend/share CAGR similar to 3088.T's 55.56%. Walter Schloss finds parallel short-term dividend strategies for both companies.
34.92%
AR growth well above 3088.T's 2.31%. Michael Burry fears inflated revenue or higher default risk in the near future.
1.59%
We show growth while 3088.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
5.03%
Asset growth above 1.5x 3088.T's 1.65%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
4.95%
BV/share growth above 1.5x 3088.T's 2.95%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-10.52%
We’re deleveraging while 3088.T stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-45.14%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.